ARTICLE | Clinical News
Valentis begins Phase I/IIa trial
March 23, 2000 8:00 AM UTC
VLTS and partner Eurogene (London, U.K.) began a 12-patient dose escalation trial in Finland with Eurogene's biodegradable collar-reservoir device for local delivery of VLTS' VEGF165 gene medicine pla...